ARIAD Pharmaceuticals

IDRx Appoints David P. Kerstein, M.D., as Chief Medical Officer

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Sumitomo Pharma, Takeda Pharmaceutical Company, Tufts University, Patient, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, Pharmaceutical industry

IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.

Key Points: 
  • IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies, today announced the appointment of David P. Kerstein, M.D., as Chief Medical Officer.
  • Dr. Kerstein brings to IDRx deep experience in early- and late-stage oncology drug development, including multiple precision oncology medicines.
  • He joins the founding IDRx R&D leadership team of Jessica Christo, Chief Development Operations Officer, and Vivek (Vic) Kadambi, Ph.D., Chief Product Development Officer.
  • Before Theseus, Dr. Kerstein served as Chief Medical Officer of Anchiano Therapeutics Ltd.

IDRx Strengthens Executive Team with Appointments of Tim Clackson, Ph.D., as CEO and Brad Dahms as CFO and CBO

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Cantor Fitzgerald, Ohio State University, Development, J. P. Morgan, Information technology, Novo Nordisk, NSCLC, Genentech, University, Brad, Patient, Research, Sale, Acquisition, Lung cancer, Research and development, Therapy, Takeda, GIST, ARIAD Pharmaceuticals, RBC Capital Markets, Forma, Drug resistance, Pharmaceutical industry

Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.

Key Points: 
  • Ben Auspitz, IDRx’s co-founder and founding CEO, and also co-founder of Forge Life Science Partners, will become Chairman of the IDRx Board of Directors.
  • He played a key role in the company's evolution from early research to a global commercial oncology company, and its subsequent acquisition by Takeda.
  • He led Selecta through several significant financing and strategic transactions, including a $730 million licensing agreement for its lead program.
  • “I look forward to working with Tim, Ben, and the team at IDRx to grow the Company with the backbone of IDRX-42,” said Mr. Dahms.

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Retrieved on: 
Monday, March 11, 2024
Therapy, Breast cancer, SAN, Pharmacology, ARIAD Pharmaceuticals, Biotechnology, Baxalta, Bone marrow, Drug development, Prostate, Acute leukemia, Acting, Stomach, Sanofi, Oxaliplatin, Astellas Pharma, Patient, Oncology, Qasr El Eyni Hospital, Stromal cell, Pancreatic cancer, IND, Head, Colorectal cancer, Cancer, Prostate cancer, Medical imaging

SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

Key Points: 
  • SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.
  • “Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.
  • “We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”
    “I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen.
  • Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc. where he led the transition of two novel cell therapy programs into clinical development.

Harvey J. Berger, M.D. Joins Kojin Therapeutics as Chairman, President, and Chief Executive Officer

Retrieved on: 
Wednesday, January 3, 2024
Oncology, Health, Genetics, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Ferroptosis, Immunology, Cameron Boyce, Broad Institute, Drug discovery, Autoimmune disease, Science, Virology, Janssen Pharmaceuticals, Research, Chemical biology, MIT, Dana–Farber Cancer Institute, Apoptosis, Conditional sentence, Yale School of Medicine, Bayer, Yang, Therapy, Cancer, Investment, Polaris Partners, ARIAD Pharmaceuticals, Medicine, Harvard University, Yale New Haven Hospital, Scripps Research, Patient, Cardiovascular disease, Colgate University, Harvard Medical School, Organization, Yale school, Wolf Prize, Pharmaceutical industry

Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.

Key Points: 
  • Kojin Therapeutics, Inc., a pioneer in cell-state and ferroptosis biology and cutting-edge drug discovery, today announced the appointment of Harvey J. Berger, M.D.
  • as its new chairman, president, and chief executive officer.
  • He founded ARIAD Pharmaceuticals and led the company from a start-up to a fully integrated global oncology company.
  • Kojin co-founder Professor Stuart Schreiber stated, “We are thrilled to welcome Dr. Berger, a long-time colleague and collaborator, as Kojin’s new chief executive.

AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Forest Laboratories, Seres, U.S. Commercial Service in Taiwan, Merck, Doctor of Philosophy, Development, Senior, Relay, Shire, Marketing, Lung cancer, Cancer, Therapy, ARIAD Pharmaceuticals, David Berry (inventor), Regulatory affairs, Pharmaceutical industry, Takeda

AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.

Key Points: 
  • AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced the appointments of Guilin Huang as Senior Vice President, Development and Amy Muse as Vice President, U.S. Commercial.
  • Amy joins AnHeart with more than 20 years of commercial experience in the pharmaceutical and biotech industry.
  • Amy will lead commercial strategy for AnHeart’s investigational precision therapies in the United States, focusing initially on preparing AnHeart for the commercial launch of taletrectinib.
  • Prior to Takeda, Amy held several commercial roles, including marketing and sales positions, at Shire, Forest Laboratories, and Merck and Co.

Summit Therapeutics Appoints Proven Biotech Leader Manmeet S. Soni as Chief Operating Officer

Retrieved on: 
Monday, October 16, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., Genentech, LLP, Drug development, Abstract, Harvard University, Pfizer, Data management, Drug, Pharmacyclics, Arena Pharmaceuticals, Therapy, SMMT, Quality of life, Lasso, PwC, Knowledge, Amgen, Biogen, AbbVie, Athenahealth, CFO, Stonehill College, Faculty, Risk, Jazz Pharmaceuticals, University, Cancer, Jazz, Trust, Nektar, Immunotherapy, CMO, Biostatistics, Information technology, Alnylam Pharmaceuticals, MD Anderson Cancer Center, Public health, Regulatory affairs, Nektar Therapeutics, Sale, Senior, Doctor of Philosophy, Licensed practical nurse, ARIAD Pharmaceuticals, Growth, Hematology, Patient, Management, Nursing, Pharmacovigilance, Robert Maki

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.

Key Points: 
  • Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Manmeet S. Soni has been appointed as the Company’s Chief Operating Officer, effective immediately.
  • “Manmeet Soni has few peers in this industry, and his track record speaks for itself,” stated Dr. Maky Zanganeh, Chief Executive Officer and President of Summit.
  • “Leveraging his leadership and wisdom on a daily basis is a powerful addition to the already formidable Team Summit.
  • I am grateful for the trust he has displayed in Maky, me, and our team in joining our mission full-time.”
    Mr. Soni has over 20 years of financial and operational leadership experience and joins Summit from Reata Pharmaceuticals, Inc., where he was President, Chief Operating Officer, & Chief Financial Officer.

C4 Therapeutics Announces Chief Financial Officer Succession

Retrieved on: 
Tuesday, September 5, 2023
Agios Pharmaceuticals, Amgen, General Electric, CCCC, GE, Research, Strategic planning, Hamilton College, ARIAD Pharmaceuticals, KPMG LLP, CFO, KPMG, Therapy, Economics, Disease, Management

WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023.

Key Points: 
  • WATERTOWN, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Kendra Adams as chief financial officer (CFO), effective September 18, 2023.
  • Ms. Adams began her professional career at General Electric, where she participated in the company’s intensive Financial Management Program.
  • After GE, she joined KPMG LLP where she led consulting teams on a variety of financial and strategic matters.
  • "We look forward to Kendra’s expanded role as our next chief financial officer and we are excited to further leverage her strategic decision making and extensive capital markets experience as we continue to advance our pipeline of degrader medicines,” said Andrew Hirsch, president and chief executive officer.

Nexo Therapeutics Launches With $60 Million Series A Financing

Retrieved on: 
Wednesday, July 26, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Yale University, University of Colorado School of Medicine, Broad Institute, Versant, University, Therapy, Cormorant, Head, Biogen, Roche, Cancer, Research, Cysteine, MIT, Harvard University, AstraZeneca, Astex Pharmaceuticals, Proteomics, MD Anderson Cancer Center, Biochemistry, Development, ARIAD Pharmaceuticals, NEA, C4, Alkermes, Patient, Associate, Drug discovery, Vertex Pharmaceuticals, Biology, MDL Information Systems, LP, New Enterprise Associates, Pharmacology, Nested, Disease, Pharmaceutical industry, Fine chemical, Nexø, Chemistry

Nexo Therapeutics today emerged from stealth with a $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management.

Key Points: 
  • Nexo Therapeutics today emerged from stealth with a $60 million Series A financing led by founding investor Versant Ventures with participation from New Enterprise Associates and Cormorant Asset Management.
  • “At Nexo, we are leveraging innovations in covalent chemistry and chemical biology to enable targeting these fundamental drivers.
  • Prior to joining Nexo, he served as Head of Discovery Biology at Nested Therapeutics where he helped build a precision oncology pipeline.
  • He has led the creation of corporate headquarters for multiple emerging biotechs and prior to joining Nexo, he held senior leadership roles at Proteovant Therapeutics, Jnana Therapeutics and C4 Therapeutics.

Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor

Retrieved on: 
Wednesday, June 28, 2023
Finance, Business, Banking, Professional Services, Other Professional Services, BLUE, Shareholder, Internet, Glenview Capital Management, Telephone, Annual, Annual Meetings of the International Monetary Fund and the World Bank Group, Wall Street, ALKS, Sequah Medicine Company, ARIAD Pharmaceuticals, ISS, Alkermes (company), Management, Security (finance), Alkermes, Sarissa

Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.

Key Points: 
  • Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.
  • If shareholders are not added to the board, we fear that Pops will continue to run the company as he pleases and never address its fundamental issues.
  • The board steadfastly refuses to add our nominees, including Sarah Schlesinger, who the Nom-Gov committee at Alkermes previously acknowledged would be a qualified board candidate and who ISS recommended that shareholders vote “FOR”.
  • Shareholders face an important decision at the upcoming Alkermes annual shareholder meeting.

Lung Cancer Therapies Market to Amplify Significantly over 2022-2029 - Brandessence Market Research

Retrieved on: 
Monday, May 29, 2023
Smoker, Atezolizumab, Complex conjugate, Lung cancer, Tobacco, Alectinib, Cough, Hospital, Acquisition, Patient, Investment, EGFR, Diffuse large B-cell lymphoma, Risk, Eli Lilly and Company, Spacecraft, Health, Air pollution, Virus, Disease, ALK, Therapy, Crizotinib, Entrectinib, Research, Paclitaxel, Boehringer Ingelheim, ARIAD Pharmaceuticals, Growth, Pembrolizumab, Smoking, Erlotinib, Docetaxel, Gas, Cancer, Osimertinib, Chest pain, Traction, Blood, Immune system, ROS1, Trastuzumab emtansine, Teva Pharmaceuticals, Radiation, Pfizer, Bristol Myers Squibb, AstraZeneca, Lung, Novartis, Smoke, Nivolumab, Pharmaceutical industry, Renewable energy, Vaccine, Bayer, Genentech, Talimogene laherparepvec

With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.

Key Points: 
  • With rapid evolution in the field of medical research, numerous therapies aimed at treating lung cancer have been developed.
  • The business intelligence report on Lung Cancer Therapies Market by Brandessence Market Research is curated with an aim to provide the industry participants with a succulent overview of this industry.
  • By treatment, the chemotherapy segment is projected to amass notable gains due to its efficacy in treating lung cancer.
  • The Lung Cancer Therapies Market is anticipated to garner significant returns over the estimated timeline of 2022-2029.